NeuroMetrix to Preview New Product Targeted at Diabetes Market at the American Association of Clinical Endocrinologists Annual Meeting

WALTHAM, Mass., Apr 13, 2011 (BUSINESS WIRE) --

NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it will preview its newest product - NC-stat^® | DPNCheck^™ - at the Annual Meeting of the American Association of Clinical Endocrinologists (AACE), taking place April 13-17 in San Diego, CA. NC-stat^® | DPNCheck^™ is a fast, accurate, and quantitative test for the evaluation of systemic neuropathies such as diabetic peripheral neuropathy (DPN).

NC-stat^® | DPNCheck^™ Benefits

• May aid in the early detection, confirmation, and monitoring of DPN
• Measures sural nerve conduction velocity - a standard biomarker for subclinical and symptomatic DPN
• Sensitive and specific for DPN^,², and predictive of its complications³
• Straightforward clinical interpretation
• Cost effective

"We are excited to preview NC-stat^® | DPNCheck^™ at AACE as it a key milestone in our aggressive timetable to launch this product into the diabetes market," said Shai N. Gozani M.D., PhD., President and Chief Executive Officer of NeuroMetrix. "This point-of-care device should help address the need for widely available, objective and standardized test for diabetic neuropathy."

NeuroMetrix encourages AACE attendees to stop by booth #506 to:

• Learn more about NC-stat^® | DPNCheck^™.
• View a live demonstration.
• Inquire about the no-obligation trial.
• Meet with NeuroMetrix representatives.

The device is a modified version of the widely used NC-stat^® device which has been shown to accurately detect DPN^,². NC-stat^® | DPNCheck^™ will be commercially available in the second half of the year. To learn more, click here.

About NeuroMetrix

NeuroMetrix is a science-based health care company transforming patient care through neurotechnology. We develop and market innovative products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders such as those associated with diabetes, carpal tunnel syndrome, lumbosacral disc disease and spinal stenosis. For more information, visit http://www.neurometrix.com.

References

¹Perkins BA, Orszag A, Grewal J, NG E, Ngo M, Bril V. Validation of a Novel Point-of-Care Nerve Conduction Device for the Detection of Diabetic Sensorimotor Polyneuropathy. Diabetes Care. September 2006;29(9): 2023-2027. ²Perkins BA, Orszag A, Grewal J, NG E, Ngo M, Bril V. Multi-Site Testing with a Point-of-Care Nerve Conduction Device Can Be Used in an Algorithm to Diagnose Diabetic Sensorimotor Polyneuropathy. Diabetes Care. March 2008;31(3): 522-524. ³Pambianco G, et al. The Assessment of Clinical Distal Symmetric Polyneuropathy in Type 1 Diabetes: A Comparison of Methodologies from the Pittsburgh Epidemiology of Diabetes Complications Cohort. Diabetes Research & Clinical Practice (2011), doi:10.1016/j.diabres.2011.02.005.

SOURCE: NeuroMetrix, Inc.

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
CFO
neurometrix.ir@neurometrix.com